Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INV-102
- Development stage
- Phase 2
- Lead developer
- Invirsa
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
INV-102 is a novel small molecule ophthalmic drug developed by Invirsa for the treatment of ocular surface diseases. It is a modified, naturally occurring compound that acts as a p53 activator and DNA repair enzyme stimulant. The mechanism involves enhancing the DNA damage response in ocular tissues by activating p53, which accelerates DNA repair and promotes tissue healing. This approach targets cellular dysfunction caused by excessive or unrepaired DNA damage—common in conditions such as dry eye disease, infectious keratoconjunctivitis (both viral and bacterial), diabetic macular edema associated with non-proliferative diabetic retinopathy, and Fuchs endothelial corneal dystrophy. Preclinical studies have shown potent healing activity with an excellent safety profile across various severe ocular conditions associated with DNA damage[2][5][7]. Clinical trials are ongoing to evaluate its efficacy in these indications.
- Other names
- Invirsa (company association)
02
Targets
TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on INV-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INV-102.